Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HES
MCID: HYP098
MIFTS: 67

Hypereosinophilic Syndrome (HES)

Categories: Blood diseases, Immune diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Hypereosinophilic Syndrome

About this section

MalaCards integrated aliases for Hypereosinophilic Syndrome:

Name: Hypereosinophilic Syndrome 12 77 54 38 56 15 17 74
Eosinophilia 12 77 30 56 45 15 74
Hes 54 49
Disseminated Eosinophilic Collagen Disease 74
Hypereosinophilic Syndrome, Idiopathic 54
Idiopathic Hypereosinophilic Syndrome 74
Eosinophilic Leukocytosis 12
Eosinophilic Disorder 74

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:999
KEGG 38 H01599
ICD9CM 36 288.3
MeSH 45 D004802
SNOMED-CT 69 27955006
ICD10 34 D72.1
Sources

Summaries for Hypereosinophilic Syndrome

About this section
NIH Rare Diseases : 54 Hypereosinophilic syndrome (HES) refers to a rare group of conditions that are associated with persistent eosinophilia with evidence of organ involvement. Signs and symptoms vary significantly based on which parts of the body are affected. Although any organ system can be involved in HES, the heart, central nervous system, skin, and respiratory tract are the most commonly affected. The condition was originally thought to be "idiopathic" or of unknown cause. However, recent advances in diagnostic testing have allowed a cause to be identified in approximately a quarter of cases. Management varies based on the severity of the condition and whether or not an underlying cause has been identified but generally includes imatinib or corticosteroids as an initial treatment.

MalaCards based summary : Hypereosinophilic Syndrome, also known as eosinophilia, is related to primary hypereosinophilic syndrome and myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1, and has symptoms including nausea and vomiting, constipation and angina pectoris. An important gene associated with Hypereosinophilic Syndrome is PDGFRA (Platelet Derived Growth Factor Receptor Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Omalizumab and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Eosinophilia is a condition in which the eosinophil count in the peripheral blood exceeds 5.0×108/l... more...

Sources

Related Diseases for Hypereosinophilic Syndrome

About this section

Diseases in the Hypereosinophilic Syndrome family:

Secondary Hypereosinophilic Syndrome Primary Hypereosinophilic Syndrome

Diseases related to Hypereosinophilic Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 840)
# Related Disease Score Top Affiliating Genes
1 primary hypereosinophilic syndrome 33.9 FGFR1 FIP1L1 PDGFRA PDGFRB
2 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 33.8 FGFR1 PDGFRA PDGFRB
3 hypereosinophilic syndrome, idiopathic 33.8 FIP1L1 IL3 IL5 KIT PDGFRA PDGFRB
4 chronic eosinophilic pneumonia 33.0 CCL11 IL5 RNASE3
5 omenn syndrome 32.5 IGHE IL4 IL5
6 endomyocardial fibrosis 32.5 FIP1L1 IL4 PDGFRA
7 eosinophilic pneumonia 31.4 CCL11 CCL17 CSF2 IL13 IL3 IL5
8 intestinal schistosomiasis 31.1 IL13 IL4 IL5
9 paragonimiasis 31.1 CCL17 IL13 IL5 RNASE3
10 chronic eosinophilic leukemia 31.1 ABL1 FGFR1 FIP1L1 IFNA1 KIT PDGFRA
11 eosinophilic colitis 30.8 PRG2 RNASE3
12 pulmonary eosinophilia 30.5 CCL11 CCL17 EPX IL13 IL4 IL5
13 churg-strauss syndrome 30.4 CCL17 IL5 RNASE3
14 wells syndrome 30.4 IL2RA IL5 RNASE3
15 loeffler endocarditis 30.3 FIP1L1 IL5 PDGFRA RNASE3
16 eosinophilic gastroenteritis 30.2 CCL11 EPX IL3 IL5 RNASE3
17 leiomyosarcoma 30.2 KIT PDGFRA PDGFRB
18 systemic mastocytosis 30.1 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
19 toxic oil syndrome 30.1 IGHE IL2RA IL4 IL5
20 gastroenteritis 30.1 CCL11 IFNA1 IL4 IL5 RNASE3
21 eosinophilic granuloma 30.1 EPX RNASE3
22 strongyloidiasis 30.0 CCL11 IL13 IL5
23 pdgfra-associated chronic eosinophilic leukemia 30.0 FIP1L1 PDGFRA
24 bullous pemphigoid 29.9 CCL11 IL5 RNASE3
25 bronchitis 29.9 CCL11 IL5 RNASE3
26 kimura disease 29.8 CCL11 IL4 IL5 RNASE3
27 pemphigoid gestationis 29.8 CCL11 IL5
28 desmoid tumor 29.8 KIT PDGFRA PDGFRB
29 myeloproliferative neoplasm 29.7 ABL1 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
30 milk allergy 29.7 IL4 IL5 RNASE3
31 cytokine deficiency 29.7 IL13 IL5
32 allergic bronchopulmonary aspergillosis 29.7 CCL17 EPX IL4 IL5
33 mastocytosis 29.7 FIP1L1 IL13 IL2RA KIT PDGFRA PDGFRB
34 mycosis fungoides 29.6 CCL17 IFNA1 IL2RA IL5
35 dermatofibrosarcoma protuberans 29.6 KIT PDGFRA PDGFRB
36 chronic myelomonocytic leukemia 29.6 CSF2 KIT PDGFRB
37 8p11 myeloproliferative syndrome 29.6 FGFR1 KIT PDGFRB
38 allergic contact dermatitis 29.6 CCL17 IL4 IL5
39 contact dermatitis 29.6 CCL17 IL4 IL5
40 folliculitis 29.6 CCL11 IL2RA IL4 IL5
41 acquired immunodeficiency syndrome 29.6 CSF2 IFNA1 IL2RA
42 cough variant asthma 29.5 IL4 IL5 RNASE3
43 esophagitis 29.5 CCL11 IL13 IL5
44 esophagitis, eosinophilic, 1 29.5 CCL11 IL13 IL5
45 aspergillosis 29.5 CCL17 CSF2 IL4 IL5
46 cutaneous t cell lymphoma 29.4 CCL17 IFNA1 IL2RA IL4
47 gastrointestinal stromal tumor 29.4 ABL1 KIT PDGFRA PDGFRB
48 polycythemia vera 29.3 ABL1 IFNA1 IL3 KIT PDGFRA PDGFRB
49 egg allergy 29.3 IGHE IL4 IL5
50 intrinsic asthma 29.3 IL3 IL4 IL5 RNASE3

Comorbidity relations with Hypereosinophilic Syndrome via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Deficiency Anemia Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Hypereosinophilic Syndrome:



Diseases related to Hypereosinophilic Syndrome
Sources

Symptoms & Phenotypes for Hypereosinophilic Syndrome

About this section

UMLS symptoms related to Hypereosinophilic Syndrome:


nausea and vomiting, constipation, angina pectoris, abdominal pain, edema, pruritus, myalgia, chest pain, diarrhea, snoring, icterus, coughing, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

27 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.68 PDGFRA
2 Decreased viability GR00221-A-1 9.68 ABL1 FGFR1 KIT PDGFRA PDGFRB
3 Decreased viability GR00221-A-2 9.68 ABL1 FGFR1
4 Decreased viability GR00221-A-3 9.68 ABL1 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 9.68 PDGFRA PDGFRB
6 Decreased viability GR00301-A 9.68 KIT
7 Decreased viability GR00342-S-1 9.68 ABL1 PDGFRB
8 Decreased viability GR00342-S-2 9.68 ABL1
9 Decreased viability GR00342-S-3 9.68 ABL1
10 Decreased viability GR00402-S-2 9.68 ABL1 FGFR1 KIT PDGFRA PDGFRB
11 Decreased substrate adherent cell growth GR00193-A-1 9.43 KIT
12 Decreased substrate adherent cell growth GR00193-A-2 9.43 ABL1 KIT
13 Decreased substrate adherent cell growth GR00193-A-4 9.43 ABL1 FGFR1 KIT

MGI Mouse Phenotypes related to Hypereosinophilic Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 ABL1 CCL11 CCL17 CSF2 EPX FGFR1
2 digestive/alimentary MP:0005381 9.97 ABL1 FGFR1 IL13 IL2RA IL4 IL5
3 craniofacial MP:0005382 9.91 ABL1 CSF2 FGFR1 IL4 KIT PDGFRA
4 endocrine/exocrine gland MP:0005379 9.91 ABL1 CSF2 FGFR1 IL13 IL2RA IL4
5 immune system MP:0005387 9.8 ABL1 CCL11 CCL17 CSF2 EPX FGFR1
6 respiratory system MP:0005388 9.32 ABL1 CCL11 CSF2 IL13 IL2RA IL4
Sources

Drugs & Therapeutics for Hypereosinophilic Syndrome

About this section

Drugs for Hypereosinophilic Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
5
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
6
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
7 Benralizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1044511-01-4
8
Prednisolone hemisuccinate Experimental Phase 4,Phase 3 2920-86-7
9 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
10 Adrenergic beta-Agonists Phase 4,Phase 2
11 Anti-Allergic Agents Phase 4,Phase 2
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Tocolytic Agents Phase 4,Phase 2
14 Adrenergic Agonists Phase 4,Phase 2
15 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
16 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Not Applicable
17 Albuterol Phase 4,Phase 2
18 Anti-Asthmatic Agents Phase 4,Phase 2,Phase 3,Not Applicable
19 Autonomic Agents Phase 4,Phase 3,Phase 2
20 Neurotransmitter Agents Phase 4,Phase 2
21 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
22 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Bronchodilator Agents Phase 4,Phase 2
24 Adrenergic Agents Phase 4,Phase 2
25 Respiratory System Agents Phase 4,Phase 2,Phase 3,Not Applicable
26 Antiemetics Phase 4,Phase 3,Phase 2
27 Methylprednisolone Acetate Phase 4,Phase 3
28 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3
29 Hormone Antagonists Phase 4,Phase 2,Phase 3
30 Neuroprotective Agents Phase 4,Phase 3
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
32 glucocorticoids Phase 4,Phase 2,Phase 3
33 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
34 Protective Agents Phase 4,Phase 3,Phase 2
35 Hormones Phase 4,Phase 3,Phase 2
36 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
37 Prednisolone acetate Phase 4,Phase 3
38
Daunorubicin Approved Phase 3 20830-81-3 30323
39
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1 147-94-4, 65-46-3 6253
40
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
41
Thioguanine Approved Phase 3 154-42-7 2723601
42
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
43
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
44
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
45 Reslizumab Approved, Investigational Phase 2, Phase 3,Phase 3
46
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
47 Bone Density Conservation Agents Phase 3
48 Calcium, Dietary Phase 3
49 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
50 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
2 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
3 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 prednisone
4 Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Not yet recruiting NCT03652376 Phase 4 Benralizumab
5 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
6 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
7 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
8 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
9 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Completed NCT02559791 Phase 2, Phase 3 Placebo
10 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
11 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
12 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
13 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
14 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
15 A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 Recruiting NCT03306043 Phase 3 Mepolizumab
16 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
17 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies Recruiting NCT03470311 Phase 3
18 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3 Placebo
19 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
20 Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome Terminated NCT00097370 Phase 3 mepolizumab
21 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Terminated NCT03052725 Phase 3 reslizumab
22 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
23 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
24 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
25 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
26 Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) Completed NCT00086658 Phase 2 mepolizumab
27 Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Completed NCT00787384 Phase 2 Imatinib
28 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
29 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) Completed NCT00483067 Phase 2 2-CdA;Ara-C;G-CSF (Granulocyte colony-stimulating factor)
30 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed NCT00255346 Phase 2 Dasatinib (BMS-354825)
31 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
32 Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Completed NCT00171912 Phase 2 imatinib mesylate
33 Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis Completed NCT00555581 Phase 2 Imatinib Mesylate
34 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
35 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
36 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
37 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
38 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2 lenalidomide
39 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
40 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
41 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
42 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
43 Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma Completed NCT03469934 Phase 2 ANB020;Placebo
44 Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Completed NCT02560610 Phase 2 OC000459;Placebo
45 A Phase IIa Study of KHK4563 Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
46 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
47 Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome Recruiting NCT00044304 Phase 2 Imatinib;Ruxolitinib
48 Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT03862157 Phase 1, Phase 2 Azacitidine;Pevonedistat;Venetoclax
49 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
50 Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome Active, not recruiting NCT02130882 Phase 2 benralizumab

Search NIH Clinical Center for Hypereosinophilic Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: eosinophilia

Sources

Genetic Tests for Hypereosinophilic Syndrome

About this section

Genetic tests related to Hypereosinophilic Syndrome:

# Genetic test Affiliating Genes
1 Eosinophilia 30
Sources

Anatomical Context for Hypereosinophilic Syndrome

About this section

MalaCards organs/tissues related to Hypereosinophilic Syndrome:

42
Myeloid, T Cells, Lung, Bone, Skin, Bone Marrow, Heart
Sources

Publications for Hypereosinophilic Syndrome

About this section

Articles related to Hypereosinophilic Syndrome:

(show top 50) (show all 2586)
# Title Authors Year
1
Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA. ( 30806106 )
2019
2
Adenosquamous carcinoma of the uterine cervix displaying tumor-associated tissue eosinophilia. ( 30800306 )
2019
3
Lethal cardiac damage resulting from eosinophilia caused by anaplastic large cell lymphoma. ( 30793295 )
2019
4
Persistent eosinophilia in rheumatoid arthritis: a prospective observational study. ( 30426234 )
2019
5
DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment. ( 30760581 )
2019
6
Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. ( 30652675 )
2019
7
Prevalence of Eosinophilic Colitis and the Diagnoses Associated with Colonic Eosinophilia. ( 30654053 )
2019
8
Eosinophilic colitis and colonic eosinophilia. ( 30480590 )
2019
9
Evaluation of Peripheral Blood Eosinophilia in Adolescent and Adult Patients Suffering from Atopic Dermatitis and the Relation to the Occurrence of Allergy to Aeroallergens. ( 30745633 )
2019
10
Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come? ( 30652265 )
2019
11
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to lamotrigine differs from that due to other drugs. ( 30663091 )
2019
12
Facial pustules due to drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms may histopathologically mimic eosinophilic pustular folliculitis: a case report. ( 30666704 )
2019
13
Comments on: Abnormal erythrocyte morphology in drug reaction with eosinophilia and systemic symptoms. ( 30685268 )
2019
14
Increased type 2 innate lymphoid cells in patients with drug reaction with eosinophilia and systemic symptom. ( 30735685 )
2019
15
Erythema Gyratum Repens as a Manifestation of Drug Reaction with Eosinophilia and Systemic Symptoms. ( 30745644 )
2019
16
HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. ( 30776417 )
2019
17
Drug reaction with eosinophilia and systemic symptoms (DRESS) in children. ( 30830064 )
2019
18
Can we allow a further intake of drugs poorly suspected as responsible in responsible in drug reaction with eosinophilia and systemic symptoms (DRESS)? A study of practice. ( 30834582 )
2019
19
Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome associated with Ethambutol use: A Case Report. ( 30848209 )
2019
20
Drug reaction with eosinophilia and systemic symptoms presenting as leukoencephalopathy. ( 30868617 )
2019
21
A Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome Associated With Clobazam. ( 30870346 )
2019
22
Oxacillin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). ( 30877266 )
2019
23
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS Syndrome). ( 30879852 )
2019
24
Case Report: Hepatic Fascioliasis in a Young Afghani Woman with Severe Wheezing, High-Grade Peripheral Eosinophilia, and Liver Lesions: A Brief Literature Review. ( 30628571 )
2019
25
Paraneoplastic hypereosinophilic syndrome associated with IL3-IgH positive acute lymphoblastic leukemia. ( 30207070 )
2019
26
Advances in diagnosis of mastocytosis and hypereosinophilic syndrome☆. ( 30573041 )
2019
27
Hypereosinophilic syndrome presenting with bilateral ear fullness. ( 30683419 )
2019
28
Idiopathic hypereosinophilic syndrome presenting with multiple organ damage: A case report. ( 30855439 )
2019
29
Idiopathic Hypereosinophilic Syndrome in an Elderly Female: A Case Report. ( 30902963 )
2019
30
Angiolymphoid hyperplasia with eosinophilia with clinical pictures of keratoacanthoma: A rare case report. ( 30656039 )
2019
31
Acute myeloid leukemia with eosinophilia after cyclin-dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential. ( 30575100 )
2019
32
Eosinophilia and Leukocytosis in a Patient with Lung Cancer. ( 30685910 )
2019
33
Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: Case report of a rare lesion with novel genetic mutation. ( 30677251 )
2019
34
A Myelodysplastic Syndrome with Concurrent Basophilia and Eosinophilia Lacking Oncogenic Mutations in 54 Relevant Genes. ( 30775878 )
2019
35
Filarial tropical pulmonary eosinophilia. ( 30720371 )
2019
36
The relationship of eosinophilia with outcomes of Hirschsprung disease in children. ( 30666416 )
2019
37
Peripheral blood eosinophilia is associated with the presence of skin ulcers in patients with systemic sclerosis. ( 30714650 )
2019
38
A Literature Review of Blood-Disseminated P. marneffei Infection and a Case Study of this Infection in an HIV-Negative Child with Comorbid Eosinophilia. ( 29524085 )
2019
39
Peripheral Eosinophilia Found in Pediatric Enterobius vermicularis Infections. ( 30280584 )
2019
40
Mycobacterial infection induces eosinophilia and production of α-defensin by eosinophils in mice. ( 30473572 )
2019
41
Prevalence and Clinical Features of Drug Reactions With Eosinophilia and Systemic Symptoms Syndrome Caused by Antituberculosis Drugs: A Retrospective Cohort Study. ( 30479080 )
2019
42
Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. ( 30573779 )
2019
43
Angiolymphoid hyperplasia with eosinophilia: Two case reports. ( 30693480 )
2019
44
Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome induced by imatinib. ( 30706827 )
2019
45
Nested case-control study investigating the diagnostic role of tissue eosinophilia in adverse cutaneous drug reactions. ( 30770612 )
2019
46
Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up. ( 30807397 )
2019
47
Clozapine-induced eosinophilia and serositis. ( 30808609 )
2019
48
Nasal and systemic eosinophilia associated with solid intestinal tumors, a case report and review of the literature. ( 30837352 )
2019
49
A novel deletion mutation in KMT2A identified in a child with ID/DD and blood eosinophilia. ( 30841869 )
2019
50
Cutaneous adverse drug reactions in patients with peripheral blood eosinophilia during antituberculosis treatment. ( 30879290 )
2019
Sources

Variations for Hypereosinophilic Syndrome

About this section
Sources

Expression for Hypereosinophilic Syndrome

About this section
Search GEO for disease gene expression data for Hypereosinophilic Syndrome.
Sources

Pathways for Hypereosinophilic Syndrome

About this section

Pathways related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 13.98 ABL1 CCL11 CSF2 EPX FGFR1 IFNA1
2
ERK Signaling 65
Show member pathways
 13.89 ABL1 CCL11 CCL17 CSF2 FGFR1 IL13
3
PEDF Induced Signaling 65
Show member pathways
 13.71 CCL11 CCL17 CSF2 FGFR1 IFNA1 IL13
4
TGF-Beta Pathway 65
Show member pathways
 13.58 CCL11 CCL17 FGFR1 IFNA1 IL13 IL2RA
5
Developmental Biology 67
Show member pathways
 13.53 ABL1 CSF2 FGFR1 IL2RA IL3 IL5
6
Akt Signaling 65
Show member pathways
 13.42 CCL11 CCL17 CSF2 FGFR1 IL13 IL2RA
7
Cytokine Signaling in Immune system 67
Show member pathways
 13.29 CCL11 CSF2 FGFR1 IFNA1 IGHE IL13
8
PAK Pathway 65
Show member pathways
 13.28 CCL11 CCL17 CSF2 FGFR1 IL13 IL2RA
9
Phospholipase-C Pathway 65
Show member pathways
 13.1 FGFR1 IL2RA IL3 KIT PDGFRA PDGFRB
10
p70S6K Signaling 65
Show member pathways
 13.09 FGFR1 IL2RA IL3 IL4 KIT PDGFRA
11
PI3K-Akt signaling pathway 38
Show member pathways
 13.06 FGFR1 IFNA1 IL2RA IL3 IL4 KIT
12
Endometrial cancer 38
Show member pathways
 12.93 ABL1 CSF2 FGFR1 IL3 KIT PDGFRA
13
Pathways in cancer 38
12.79 ABL1 FGFR1 IFNA1 IL13 IL2RA IL3
14
Ras signaling pathway 38
Show member pathways
 12.74 ABL1 FGFR1 KIT PDGFRA PDGFRB
15
Allograft rejection 1 38
Show member pathways
 12.67 ABL1 CCL11 EPX IFNA1 IL13 IL2RA
16
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.65 CSF2 IGHE IL13 IL3 IL4 IL5
17
NF-kappaB Signaling 4
12.6 IFNA1 IL2RA IL3 IL4 KIT
18
Apoptosis Pathway 73
Show member pathways
 12.53 FGFR1 IL13 IL2RA IL5 PDGFRA PDGFRB
19
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.49 CSF2 IFNA1 IL3 IL4
20
IL-17 Family Signaling Pathways 66
Show member pathways
 12.43 CCL11 CCL17 CSF2 IL13 IL4 IL5
21
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.4 FGFR1 IL3 KIT PDGFRA PDGFRB
22
Human T-cell leukemia virus 1 infection 38
12.35 CSF2 IL2RA PDGFRA PDGFRB
23
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.32 ABL1 CSF2 IFNA1 IL13 IL2RA IL3
24
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.2 FGFR1 IL2RA PDGFRA PDGFRB
25
Tyrosine Kinases / Adaptors 4
12.2 ABL1 FGFR1 KIT PDGFRA PDGFRB
26
G beta-gamma signalling through PI3Kgamma 67
Show member pathways
 12.18 CSF2 IL2RA IL3 IL5
27
AKT Signaling Pathway 68
12.16 FGFR1 IL2RA PDGFRA PDGFRB
28
Immune response IFN gamma signaling pathway 23
Show member pathways
 12.15 CCL11 CCL17 FGFR1 IL13 IL2RA IL3
29
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
12.09 CSF2 IL2RA IL3 IL4 IL5 KIT
30
Interleukin-4 and 13 signaling 67
12.03 CCL11 IGHE IL13 IL4
31
Hematopoietic cell lineage 38
11.99 CSF2 IL2RA IL3 IL4 IL5 KIT
32
Jak-Stat Signaling Pathway (sino) 68
11.93 ABL1 IFNA1 IL2RA IL3
33
Innate Lymphoid Cell Differentiation Pathways 66
11.91 IL13 IL2RA IL4 IL5 KIT
34
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.88 CSF2 IL2RA IL3 IL4 IL5
35
Glucocorticoid receptor regulatory network 1
11.87 CSF2 IL13 IL4 IL5
36
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.85 CCL11 CCL17 CSF2 IL13 IL4
37
Angiogenesis (CST) 4
11.84 FGFR1 PDGFRA PDGFRB
38
Imatinib Pathway, Pharmacokinetics/Pharmacodynamics 62
Show member pathways
 11.84 ABL1 KIT PDGFRA PDGFRB
39
VEGF Pathway (Tocris) 73
Show member pathways
 11.8 FGFR1 KIT PDGFRB
40
IL4-mediated signaling events 1
11.79 CCL11 CCL17 IGHE IL4 IL5
41
Lung fibrosis 1
11.78 CCL11 CSF2 IL13 IL4 IL5
42
Central carbon metabolism in cancer 38
11.76 FGFR1 KIT PDGFRA PDGFRB
43
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 11.57 ABL1 FGFR1 IFNA1 IL13 IL2RA IL3
44
Interleukin-10 signaling 67
11.56 CSF2 IL13 IL4
45
Hematopoietic Stem Cell Differentiation 1
11.55 CSF2 IL3 IL5
46
Th2 Differentiation Pathway 66
11.54 CCL11 CCL17 IL13 IL2RA IL4 IL5
47
Alzheimers Disease Pathway 65
11.52 FGFR1 PDGFRA PDGFRB
48
Vemurafenib Pathway, Pharmacodynamics 62
11.5 FGFR1 PDGFRA PDGFRB
49
Inflammatory Response Pathway 1
11.37 IL2RA IL4 IL5
50
Development and heterogeneity of the ILC family 1
11.36 IL13 IL4 IL5
Sources

GO Terms for Hypereosinophilic Syndrome

About this section

Cellular components related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL11 CCL17 CSF2 EPX IFNA1 IL13
2 receptor complex GO:0043235 9.56 FGFR1 KIT PDGFRA PDGFRB
3 external side of plasma membrane GO:0009897 9.55 IGHE IL13 IL2RA KIT PDGFRA
4 extracellular region GO:0005576 9.44 CCL11 CCL17 CSF2 EPX FGFR1 IFNA1

Biological processes related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.96 EPX IGHE PRG2 RNASE3
2 positive regulation of cell migration GO:0030335 9.96 CCL11 KIT PDGFRA PDGFRB
3 regulation of cell proliferation GO:0042127 9.94 ABL1 CSF2 FGFR1 KIT
4 positive regulation of protein kinase B signaling GO:0051897 9.93 FGFR1 KIT PDGFRA PDGFRB
5 chemotaxis GO:0006935 9.91 CCL11 CCL17 PDGFRA PDGFRB
6 positive regulation of MAPK cascade GO:0043410 9.88 FGFR1 KIT PDGFRA PDGFRB
7 protein autophosphorylation GO:0046777 9.88 ABL1 FGFR1 KIT PDGFRA PDGFRB
8 MAPK cascade GO:0000165 9.86 CSF2 FGFR1 IL2RA IL3 IL5 KIT
9 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.85 KIT PDGFRA PDGFRB
10 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.85 ABL1 IL3 IL5
11 cell chemotaxis GO:0060326 9.85 KIT PDGFRA PDGFRB
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 ABL1 CCL11 CCL17 KIT PDGFRA PDGFRB
13 immune response GO:0006955 9.85 CCL11 CCL17 CSF2 IGHE IL13 IL2RA
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 CSF2 IL13 IL3 IL4 KIT
15 positive regulation of MAP kinase activity GO:0043406 9.82 FGFR1 KIT PDGFRB
16 phosphatidylinositol phosphorylation GO:0046854 9.81 FGFR1 KIT PDGFRA PDGFRB
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.8 FGFR1 KIT PDGFRA PDGFRB
18 phosphatidylinositol-mediated signaling GO:0048015 9.78 FGFR1 PDGFRA PDGFRB
19 positive regulation of B cell proliferation GO:0030890 9.77 IL13 IL4 IL5
20 negative regulation of endothelial cell apoptotic process GO:2000352 9.75 ABL1 IL13 IL4
21 platelet-derived growth factor receptor signaling pathway GO:0048008 9.71 ABL1 PDGFRA PDGFRB
22 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.7 KIT PDGFRA PDGFRB
23 embryonic hemopoiesis GO:0035162 9.68 IL3 KIT
24 negative regulation of apoptotic process GO:0043066 9.68 IL4 PDGFRB
25 dendritic cell differentiation GO:0097028 9.67 CSF2 IL4
26 positive regulation of podosome assembly GO:0071803 9.66 CSF2 IL5
27 response to fluid shear stress GO:0034405 9.65 CSF2 PDGFRB
28 retina vasculature development in camera-type eye GO:0061298 9.65 PDGFRA PDGFRB
29 mast cell chemotaxis GO:0002551 9.62 CCL11 KIT
30 positive regulation of phospholipase C activity GO:0010863 9.62 FGFR1 KIT PDGFRA PDGFRB
31 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.6 ABL1 PDGFRB
32 metanephric glomerular capillary formation GO:0072277 9.57 PDGFRA PDGFRB
33 negative regulation of complement-dependent cytotoxicity GO:1903660 9.56 IL13 IL4
34 peptidyl-tyrosine phosphorylation GO:0018108 9.56 ABL1 CSF2 FGFR1 IL3 IL5 KIT
35 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.55 PDGFRA PDGFRB
36 cytokine-mediated signaling pathway GO:0019221 9.32 CCL11 CSF2 IFNA1 IGHE IL13 IL2RA
37 protein phosphorylation GO:0006468 10.1 ABL1 CCL11 FGFR1 KIT PDGFRA PDGFRB
38 inflammatory response GO:0006954 10.03 CCL11 CCL17 IL13 IL5 KIT
39 regulation of signaling receptor activity GO:0010469 10.01 CCL11 CCL17 CSF2 IFNA1 IL13 IL3
40 positive regulation of cell proliferation GO:0008284 10 CSF2 FGFR1 IL3 IL5 KIT PDGFRA

Molecular functions related to Hypereosinophilic Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.88 ABL1 FGFR1 KIT PDGFRA PDGFRB
2 cytokine activity GO:0005125 9.76 CCL11 CCL17 CSF2 IFNA1 IL13 IL3
3 growth factor activity GO:0008083 9.73 CSF2 IL3 IL4 IL5
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.62 FGFR1 KIT PDGFRA PDGFRB
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.56 FGFR1 KIT PDGFRA PDGFRB
6 protein tyrosine kinase activity GO:0004713 9.56 ABL1 CSF2 FGFR1 IL3 IL5 KIT
7 cytokine receptor binding GO:0005126 9.54 IFNA1 IL13 IL4
8 platelet-derived growth factor receptor binding GO:0005161 9.49 PDGFRA PDGFRB
9 platelet-derived growth factor binding GO:0048407 9.46 PDGFRA PDGFRB
10 vascular endothelial growth factor binding GO:0038085 9.4 PDGFRA PDGFRB
11 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.23 CSF2 FGFR1 IL2RA IL3 IL5 KIT
Sources

Sources for Hypereosinophilic Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....